Evidence map›Paper›PMID 20871992›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2011

Positron emission mammography in breast cancer presurgical planning: comparisons with magnetic resonance imaging.

Kathy Schilling, Deepa Narayanan, Judith E Kalinyak, Juliette The, Maria Victoria Velasquez, Simone Kahn, Matthew Saady, Ravinder Mahal, Larraine Chrystal

Abstract readClinical TrialComparative Study
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Dedicated phantom tools using traceableRadiological physics and technology · 2023
    Article
  9. The Role of PET/CT in Breast Cancer.Diagnostics (Basel, Switzerland) · 2023
    Review
  10. Review
  11. Article
  12. Augmented Whole-Body Scanning via Magnifying PET.IEEE transactions on medical imaging · 2020
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Use of Breast-Specific PET Scanners and Comparison with MR Imaging.Magnetic resonance imaging clinics of North America · 2018
    Review
  18. The value of 18F-FDG PET/CT imaging in breast cancer staging.Bosnian journal of basic medical sciences · 2018
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kathy SchillingRadiology Department, Boca Raton Regional Hospital, 800 Meadows Road, Boca Raton, FL 33486, USA. KSchilling@brch.com
Deepa Narayanan
Judith E Kalinyak
Juliette The
Maria Victoria Velasquez
Simone Kahn
Matthew Saady
Ravinder Mahal
Larraine Chrystal

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe objective of this study was to compare the performance characteristics of (18)F-fluorodeoxyglucose (FDG) positron emission mammography (PEM) with breast magnetic resonance imaging (MRI) as a presurgical imaging and planning option for index and ipsilateral lesions in patients with newly diagnosed, biopsy-proven breast cancer.

methodsTwo hundred and eight women >25 years of age (median age = 59.7 ± 14.1 years) with biopsy-proven primary breast cancer enrolled in this prospective, single-site study. MRI, PEM, and whole-body positron emission tomography (WBPET) were conducted on each patient within 7 business days. PEM and WBPET images were acquired on the same day after intravenous administration of 370 MBq of FDG (median = 432.9 MBq). PEM and MRI images were blindly evaluated, compared with final surgical histopathology, and the sensitivity determined. Substudy analysis compared the sensitivity of PEM versus MRI in patients with different menopausal status, breast density, and use of hormone replacement therapy (HRT) as well as determination of performance characteristics for additional ipsilateral lesion detection.

resultsTwo hundred and eight patients enrolled in the study of which 87% (182/208) were analyzable. Of these analyzable patients, 26.4% (48/182), 7.1% (13/182), and 64.2% (120/182) were pre-, peri-, and postmenopausal, respectively, and 48.4% (88/182) had extremely or heterogeneously dense breast tissue, while 33.5% (61/182) had a history of HRT use. Ninety-two percent (167/182) underwent core biopsy for index lesion diagnosis. Invasive cancer was found in 77.5% (141/182), while ductal carcinoma in situ (DCIS) and/or Paget's disease were found in 22.5% (41/182) of patients. Both PEM and MRI had index lesion depiction sensitivity of 92.8% and both were significantly better than WBPET (67.9%, p < 0.001, McNemar's test). For index lesions, PEM and MRI had equivalent sensitivity of various tumors, categorized by tumor stage as well as similar invasive tumor size predictions with Spearman's correlation coefficient of 0.61 for both PEM and MRI compared to surgical pathology. Menopausal status, breast density, and HRT did not influence the sensitivity of PEM or MRI. For 67 additional unsuspected ipsilateral lesions or multifocal lesions, PEM had sensitivity of 85% (34/40) and specificity of 74%, (20/27) compared to MRI's sensitivity of 98% (39/40) and specificity of 48% (13/27) [p = 0.074, for sensitivity; p = 0.096 for specificity]

conclusionPEM is a good alternative to MRI as a presurgical breast imaging option and its performance characteristics are not affected by patient menopausal/hormonal status or breast density.

Indexed as

AdultAgedAged, 80 and overBreast NeoplasmsFemaleHormone Replacement TherapyHumansMagnetic Resonance ImagingMammographyMenopauseMiddle AgedPositron-Emission TomographyRadiation DosageWhole Body Imaging

Identifiers

PMID20871992
PMCPMC3005116

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.